Aurinia Pharmaceuticals (AUPH) Income from Continuing Operations (2019 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Income from Continuing Operations came in at 34355000.0 in Q1 2026, up 47.17% YoY from 23344000.0 in Q1 2025, and down 83.7% on a QoQ basis from 210794000.0 in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 8 years of Income from Continuing Operations data on file, last reported at 34355000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 47.17% year-over-year to 34355000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 298267000.0 (up 648.47% YoY) and the FY2025 annual result came in at 287202000.0, up 4893.08% from the prior year.
- Income from Continuing Operations declined to 34355000.0 in Q1 2026, from 210794000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 210794000.0 in Q4 2025 to a low of 37630000.0 in Q1 2022.
- A 5-year average of 8308294.12 and a median of 8989000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations slumped 49.62% — and 2025, when it jumped 14171.77%.
- Tracing AUPH's Income from Continuing Operations over 5 years: stood at 26018000.0 in 2022, then retreated by 3.26% to 26867000.0 in 2023, then jumped by 105.5% to 1477000.0 in 2024, then jumped by 14171.77% to 210794000.0 in 2025, then tumbled by 83.7% to 34355000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 34355000.0 (Q1 2026), 210794000.0 (Q4 2025), and 31562000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 37.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.39 Mn |
| Mar 31, 2026 | 34.36 Mn |
| Dec 31, 2025 | 210.79 Mn |
| Sep 30, 2025 | 31.56 Mn |
| Jun 30, 2025 | 21.56 Mn |
| Mar 31, 2025 | 23.34 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 14.31 Mn |
| Jun 30, 2024 | 722,000.00 |
| Mar 31, 2024 | -10.71 Mn |
| Dec 31, 2023 | -26.87 Mn |
| Sep 30, 2023 | -13.45 Mn |
| Jun 30, 2023 | -11.49 Mn |
| Mar 31, 2023 | -26.21 Mn |
| Dec 31, 2022 | -26.02 Mn |
| Sep 30, 2022 | -8.99 Mn |
| Jun 30, 2022 | -35.52 Mn |
| Mar 31, 2022 | -37.63 Mn |
| Dec 31, 2021 | -33.32 Mn |
| Sep 30, 2021 | -50.26 Mn |